Euro. Il-10 produced by B cells in neutralized mice can effectively fight hepatitis C virus infection.

Innovation point pan Qin and his collaborators found that targeting B10 cells specifically can reduce the virus titer in mice infected with hepatitis C virus, promote specific cell killing effect, and enhance the body's anti HCV infection effect.key words hepatitis C virus, B10 cells, immunotherapy, viral titer, killer T cells, hepatitis C virus (HCV) is the main pathogen of human liver diseases.HCV infection is distributed worldwide. According to who statistics, there are about 70 million chronic hepatitis C patients in the world.HCV can cause acute and chronic infection.15-45% of patients with acute infection will spontaneously remove the virus, and 55-85% of patients will form chronic infection.about 15-30% of patients with chronic infection develop liver cirrhosis or even liver cancer, which poses a great threat to the health and life of patients.it is necessary to further explore the pathogenesis of HCV and provide new targets for HCV treatment.interleukin-10 (IL-10) - producing B cells (B10 cells) is a newly discovered immune regulatory cell, which has the function of inhibiting cellular immunity and plays a negative regulatory role in tumor and various microbial infections.Associate Professor Pan Qin of School of basic medicine of Wuhan University and his collaborators studied the role of B10 cells in HCV infection.their study showed that the proportion of B10 cells infected with HCV was up-regulated, and these B10 cells were mainly concentrated in cd19hi and cd1dhicd5 + cell groups.in mouse B cell experiment, it was found that HCV could activate MyD88 signal pathway, activate NF - κ B and AP-1 molecules by binding TLR2 receptor on B cell surface, and promote B cells to secrete inhibitory cytokine IL-10, so as to inhibit other immune active cells, participate in mediating HCV immune escape and cause HCV infection chronicity.they prepared a recombinant DNA plasmid pccd19scfv-il-10r, which specifically neutralized the secretion of IL-10 by B cells.by intramuscular injection of this plasmid into mice, mice could synthesize and secrete protein molecules containing anti-CD19 single chain variable region fragment (cd19scfv) and extracellular domain structure of IL-10 receptor alpha chain (IL-10RA).the molecule can bind to B cell CD19 molecule through cd19scfv, and capture the IL-10 secreted by B cells by using the IL-10RA structure in the molecule, which plays a specific role in blocking B10 cells.in a humanized mouse model of HCV infection, they injected mice with pccd19scfv-il-10r.the results showed that B10 cells in spleen and liver were significantly decreased, the specific immune response of cytotoxic CD8 + T cells was enhanced, and the viral load in mice was significantly reduced.their studies suggest that specific targeting of B10 cells can be used as a new strategy to enhance anti HCV immunity and has potential clinical application prospects. the results were published in the European Journal of Immunology (DOI: 10.1002 / Eji. 201948488), with Liu Min, Chen Hanyu and Luo Liang as the co authors